📊 ACH Key Takeaways
Is Accendra Health Inc./VA/ (ACH) a Good Investment?
Accendra Health demonstrates severe financial distress with negative stockholders' equity of -$461M, indicating liabilities exceed assets and shareholders have lost their stake. The company is burning cash with -$360.9M free cash flow while generating substantial operating losses (-$1.1B net income), coupled with deteriorating liquidity ratios that signal imminent solvency risk.
Fundamentals indicate severe financial stress: the business is barely profitable at the operating level, but large below-the-line losses drive a deeply negative net margin and materially weaken the balance sheet. Liquidity is tight, leverage is heavy, and cash flow is substantially negative, so modest revenue growth does not currently translate into durable earnings quality or financial stability.
Why Buy Accendra Health Inc./VA/ Stock? ACH Key Strengths
- Revenue growth of 3.1% YoY indicates modest market demand despite financial struggles
- Reasonable gross margin of 19% demonstrates some pricing power at the product level
- Cash position of $282M provides temporary buffer for operational needs
- Revenue is still growing modestly year over year, indicating underlying demand has not collapsed
- Gross margin of 19.0% suggests the core distribution business retains some gross profit generation capacity
- Cash balance of $281.99M provides limited near-term liquidity support despite overall stress
ACH Stock Risks: Accendra Health Inc./VA/ Investment Risks
- Negative stockholders' equity of -$461M represents technical insolvency and shareholder equity destruction
- Negative free cash flow of -$360.9M with net loss of -$1.1B indicates unsustainable business model
- Critical liquidity crisis with current ratio of 0.58x and quick ratio of 0.50x - unable to cover short-term obligations
- Long-term debt of $1.8B against negative equity creates structural bankruptcy risk
- Interest coverage of 0.3x means operating income cannot service debt obligations
- Negative operating cash flow of -$170M despite positive revenue indicates operational dysfunction
- Net loss of $1.10B and net margin of -39.8% indicate extremely weak earnings quality and major non-operating or impairment-related pressure
- Negative stockholders equity, current ratio of 0.58x, and interest coverage of 0.3x point to elevated solvency and refinancing risk
- Negative operating cash flow and free cash flow show the business is not self-funding and may require asset sales, restructuring, or external capital
Key Metrics to Watch
- Quarterly cash burn rate and operating cash flow trajectory
- Debt covenant compliance and refinancing activities
- Gross margin sustainability and operating expense reduction initiatives
- Operating cash flow and free cash flow trend
- Interest coverage and current ratio
Accendra Health Inc./VA/ (ACH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
ACH Profit Margin, ROE & Profitability Analysis
ACH vs Healthcare Sector: How Accendra Health Inc./VA/ Compares
How Accendra Health Inc./VA/ compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Accendra Health Inc./VA/ Stock Overvalued? ACH Valuation Analysis 2026
Based on fundamental analysis, Accendra Health Inc./VA/ has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Accendra Health Inc./VA/ Balance Sheet: ACH Debt, Cash & Liquidity
ACH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Accendra Health Inc./VA/'s revenue has declined by 72% over the 5-year period, indicating business contraction. The most recent EPS of $-0.53 indicates the company is currently unprofitable.
ACH Revenue Growth, EPS Growth & YoY Performance
ACH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $686.8M | -$12.8M | $-0.16 |
| Q2 2025 | $660.4M | -$21.9M | $-0.42 |
| Q1 2025 | $2.6B | -$21.9M | $-0.29 |
| Q3 2024 | $2.6B | -$6.4M | $-0.08 |
| Q2 2024 | $2.6B | -$21.9M | $-0.37 |
| Q1 2024 | $2.5B | -$21.9M | $-0.29 |
| Q3 2023 | $2.5B | -$6.4M | $-0.08 |
| Q2 2023 | $2.5B | -$24.4M | $0.37 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Accendra Health Inc./VA/ Dividends, Buybacks & Capital Allocation
ACH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Accendra Health Inc./VA/ (CIK: 0000075252)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACH
What is the AI rating for ACH?
Accendra Health Inc./VA/ (ACH) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 95% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACH's key strengths?
Claude: Revenue growth of 3.1% YoY indicates modest market demand despite financial struggles. Reasonable gross margin of 19% demonstrates some pricing power at the product level. ChatGPT: Revenue is still growing modestly year over year, indicating underlying demand has not collapsed. Gross margin of 19.0% suggests the core distribution business retains some gross profit generation capacity.
What are the risks of investing in ACH?
Claude: Negative stockholders' equity of -$461M represents technical insolvency and shareholder equity destruction. Negative free cash flow of -$360.9M with net loss of -$1.1B indicates unsustainable business model. ChatGPT: Net loss of $1.10B and net margin of -39.8% indicate extremely weak earnings quality and major non-operating or impairment-related pressure. Negative stockholders equity, current ratio of 0.58x, and interest coverage of 0.3x point to elevated solvency and refinancing risk.
What is ACH's revenue and growth?
Accendra Health Inc./VA/ reported revenue of $2.8B.
Does ACH pay dividends?
Accendra Health Inc./VA/ does not currently pay dividends.
Where can I find ACH SEC filings?
Official SEC filings for Accendra Health Inc./VA/ (CIK: 0000075252) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACH's EPS?
Accendra Health Inc./VA/ has a diluted EPS of $-14.31.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Accendra Health Inc./VA/ has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACH stock overvalued or undervalued?
Valuation metrics for ACH: ROE of N/A (sector avg: 15%), net margin of -39.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ACH stock in 2026?
Our dual AI analysis gives Accendra Health Inc./VA/ a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACH's free cash flow?
Accendra Health Inc./VA/'s operating cash flow is $-170.0M, with capital expenditures of $191.0M. FCF margin is -13.1%.
How does ACH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -39.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.58 (avg: 2).